Cigarette smoking induces insulin resistance: Partly via ASP-C5L2 pathway?

Bioscience Hypotheses

Volumn 2, Issue 4, 2009, Pages 267-269

  Li, Wenlong ^a   Hui, Rutai ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Acylation stimulating protein; Insulin resistance; Smoke

Indexed keywords

ACYLATION STIMULATING PROTEIN; COMPLEMENT COMPONENT C5A; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ADIPOCYTE; ARTICLE; CIGARETTE SMOKING; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 70350144284     PISSN: 17562392     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bihy.2009.04.008     Document Type: Article

References (39)

1. Freund K.M., Belanger A.J., D'Agostino R.B., and Kannel W.B. The health risks of smoking. The Framingham study: 34 years of follow-up. Ann Epidemiol 3 (1993) 417-424
2. Blair S.N., Shaten J., Brownell K., Collins G., and Lissner L. Body weight change, all-cause mortality, and cause-specific mortality in the multiple risk factor intervention trial. Ann Intern Med 119 (1993) 749-757
3. Heidrich J., Wellmann J., Heuschmann P.U., Kraywinkel K., and Keil U. Mortality and morbidity from coronary heart disease attributable to passive smoking. Eur Heart J 28 (2007) 2498-2502
4. Ezzati M., and Lopez A.D. Estimates of global mortality attributable to smoking in 2000. Lancet 362 (2003) 847-852
5. Kannel W.B., D'Agostino R.B., and Belanger A.J. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham study. Am Heart J 113 (1987) 1006-1010
6. Ludvig J., Miner B., and Eisenberg M.J. Smoking cessation in patients with coronary artery disease. Am Heart J 149 (2005) 565-572
7. Church D.F., and Pryor W.A. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 64 (1985) 111-126
8. Ronnemaa T., Ronnemaa E.M., Puukka P., Pyorala K., and Laakso M. Smoking is independently associated with high plasma insulin levels in nondiabetic men. Diabetes Care 19 (1996) 1229-1232
9. Reaven G., and Tsao P.S. Insulin resistance and compensatory hyperinsulinemia: the key player between cigarette smoking and cardiovascular disease?. J Am Coll Cardiol 41 (2003) 1044-1047
10. Eliasson B., Attvall S., Taskinen M.R., and Smith U. Smoking cessation improves insulin sensitivity in healthy middle-aged men. Eur J Clin Invest 27 (1997) 450-456
11. Murray I., Parker R.A., Kirchgessner T.G., et al. Functional bioactive recombinant acylation stimulating protein is distinct from C3a anaphylatoxin. J Lipid Res 38 (1997) 2492-2501
12. Maslowska M., Vu H., Phelis S., et al. Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur J Clin Invest 29 (1999) 679-686
13. Cianflone K., Lu H., Smith J., Yu W., and Wang H. Adiponectin, acylation stimulating protein and complement C3 are altered in obesity in very young children. Clin Endocrinol (Oxf) 62 (2005) 567-572
14. Robbins R.A., Nelson K.J., Gossman G.L., Koyama S., and Rennard S.I. Complement activation by cigarette smoke. Am J Physiol 260 (1991) L254-L259
15. Jazet I.M., Pijl H., and Meinders A.E. Adipose tissue as an endocrine organ: impact on insulin resistance. Neth J Med 61 (2003) 194-212
16. Cianflone K., Zakarian R., Couillard C., Delplanque B., Despres J.P., and Sniderman A. Fasting acylation-stimulating protein is predictive of postprandial triglyceride clearance. J Lipid Res 45 (2004) 124-131
17. Germinario R., Sniderman A.D., Manuel S., Lefebvre S.P., Baldo A., and Cianflone K. Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. Metabolism 42 (1993) 574-580
18. Tao Y., Cianflone K., Sniderman A.D., Colby-Germinario S.P., and Germinario R.J. Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line. Biochim Biophys Acta 1344 (1997) 221-229
19. Maslowska M., Sniderman A.D., Germinario R., and Cianflone K. ASP stimulates glucose transport in cultured human adipocytes. Int J Obes Relat Metab Disord 21 (1997) 261-266
20. Cline G.W., Petersen K.F., Krssak M., et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341 (1999) 240-246
21. Yasruel Z., Cianflone K., Sniderman A.D., Rosenbloom M., Walsh M., and Rodriguez M.A. Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue. Lipids 26 (1991) 495-499
22. Van Harmelen V., Reynisdottir S., Cianflone K., et al. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem 274 (1999) 18243-18251
23. Cianflone K., Kalant D., Marliss E.B., Gougeon R., and Sniderman A.D. Response of plasma ASP to a prolonged fast. Int J Obes Relat Metab Disord 19 (1995) 604-609
24. Murray I., Sniderman A.D., and Cianflone K. Mice lacking acylation stimulating protein (ASP) have delayed postprandial triglyceride clearance. J Lipid Res 40 (1999) 1671-1676
25. Ahren B., Havel P.J., Pacini G., and Cianflone K. Acylation stimulating protein stimulates insulin secretion. Int J Obes Relat Metab Disord 27 (2003) 1037-1043
26. Cianflone K., and Maslowska M. Differentiation-induced production of ASP in human adipocytes. Eur J Clin Invest 25 (1995) 817-825
27. Ozata M., Oktenli C., Gulec M., et al. Increased fasting plasma acylation-stimulating protein concentrations in nephrotic syndrome. J Clin Endocrinol Metab 87 (2002) 853-858
28. Cianflone K., Zhang X.J., Genest Jr. J., and Sniderman A. Plasma acylation-stimulating protein in coronary artery disease. Arterioscler Thromb Vasc Biol 17 (1997) 1239-1244
29. Yesilova Z., Ozata M., Oktenli C., et al. Increased acylation stimulating protein concentrations in nonalcoholic fatty liver disease are associated with insulin resistance. Am J Gastroenterol 100 (2005) 842-849
30. Schrauwen P., Hesselink M.K., Jain M., and Cianflone K. Acylation-stimulating protein: effect of acute exercise and endurance training. Int J Obes (Lond) 29 (2005) 632-638
31. Kalant D., Cain S.A., Maslowska M., Sniderman A.D., Cianflone K., and Monk P.N. The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein. J Biol Chem 278 (2003) 11123-11129
32. Kalant D., MacLaren R., Cui W., et al. C5L2 is a functional receptor for acylation-stimulating protein. J Biol Chem 280 (2005) 23936-23944
33. Maslowska M.H., Sniderman A.D., MacLean L.D., and Cianflone K. Regional differences in triacylglycerol synthesis in adipose tissue and in cultured preadipocytes. J Lipid Res 34 (1993) 219-228
34. MacLaren R., Kalant D., and Cianflone K. The ASP receptor C5L2 is regulated by metabolic hormones associated with insulin resistance. Biochem Cell Biol 85 (2007) 11-21
35. Li Y.T., He B., and Wang Y.Z. Exposure to cigarette smoke upregulates AP-1 activity and induces TNF-alpha overexpression in mouse lungs. Inhal Toxicol 21 (2009) 641-647
36. Paglialunga S., Schrauwen P., Roy C., et al. Reduced adipose tissue triglyceride synthesis and increased muscle fatty acid oxidation in C5L2 knockout mice. J Endocrinol 194 (2007) 293-304
37. Cui W., Paglialunga S., Kalant D., et al. Acylation-stimulating protein/C5L2-neutralizing antibodies alter triglyceride metabolism in vitro and in vivo. Am J Physiol Endocrinol Metab 293 (2007) E1482-E1491
38. Marcil M., Vu H., Cui W., et al. Identification of a novel C5L2 variant (S323I) in a French Canadian family with familial combined hyperlipemia. Arterioscler Thromb Vasc Biol 26 (2006) 1619-1625
39. Russell A.P. Lipotoxicity: the obese and endurance-trained paradox. Int J Obes Relat Metab Disord 28 Suppl. 4 (2004) S66-S71